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Abstract
Background: The persistence of malaria as an endemic infection and one of the major causes of childhood death in most
parts of Africa has lead to a radical new call for a global effort towards eradication. With the deployment of a highly effective
vaccine still some years away, there has been an increased focus on interventions which reduce exposure to infection in the
individual and –by reducing onward transmission-at the population level. The development of appropriate monitoring of
these interventions requires an understanding of the timescales of their effect.
Methods & Findings: Using a mathematical model for malaria transmission which incorporates the acquisition and loss of
both clinical and parasite immunity, we explore the impact of the trade-off between reduction in exposure and decreased
development of immunity on the dynamics of disease following a transmission-reducing intervention such as insecticide-
treated nets. Our model predicts that initially rapid reductions in clinical disease incidence will be observed as transmission
is reduced in a highly immune population. However, these benefits in the first 5–10 years after the intervention may be
offset by a greater burden of disease decades later as immunity at the population level is gradually lost. The negative
impact of having fewer immune individuals in the population can be counterbalanced either by the implementation of
highly-effective transmission-reducing interventions (such as the combined use of insecticide-treated nets and insecticide
residual sprays) for an indefinite period or the concurrent use of a pre-erythrocytic stage vaccine or prophylactic therapy in
children to protect those at risk from disease as immunity is lost in the population.
Conclusions: Effective interventions will result in rapid decreases in clinical disease across all transmission settings while
population-level immunity is maintained but may subsequently result in increases in clinical disease many years later as
population-level immunity is lost. A dynamic, evolving intervention programme will therefore be necessary to secure
substantial, stable reductions in malaria transmission.
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Introduction
Previous attempts at malaria eradication failed, in part, because
of a lack of political will to sustain control efforts in the face of
apparently diminishing returns [1]. A better understanding of the
effect of reducing malaria transmission on the dynamics of
infection and disease is essential if 21
st century attempts to
eliminate malaria are to be more successful than those of the 20
th
century. One of the most effective interventions currently
recommended for reducing the burden of malaria infection and
disease is the use of insecticide treated bed-nets (ITNs). ITNs
reduce the number of anopholenes within a household by both
repelling and killing mosquitoes and thus reduce the number of
infectious bites received; ITNs thus reduce the incidence of
infection and onward transmission [2]. Recently, a population-
based analysis of the roll-out of ITNs across Kenya demonstrated
that such interventions, if implemented with high coverage, could
have a significant impact on the incidence of clinical disease at a
national level [3], although it remains difficult to identify the
impact of ITN in the general trends in decreasing malaria
incidence now being reported across Africa [4,5]. This has lead to
a shift in guidance on interventions, with ITNs now promoted as
the primary intervention across all transmission settings, and a key
tool for those who consider eradication feasible [6]. In addition to
ITNs, intermittent preventive therapy (IPT) is being widely studied
as an intervention to reduce morbidity in infants (IPTi), children
(IPTc) and pregnant women (IPTp). Several trials of IPTi have
reported significant reductions in clinical disease [7]. Precisely how
IPT protects against disease is unclear but is likely to be via a
combination of clearance of existing blood stage infections and
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immunity, levels of drug resistance and transmission dynamics
[9,10]. These interventions should work alongside improvements
in diagnosis, clinical management and living conditions to reduce
the morbidity and mortality associated with malaria infection [11].
Whilst there is no doubt that both ITNs and IPT will decrease
the immediate risk of disease, concern remains that any exposure-
reducing interventions, if implemented in highly endemic settings,
could result in loss of (or failure to acquire) protective immunity
and increase the overall burden of disease in the long term. Such
concerns were highlighted by the observation that hospital
admission rates for severe malaria amongst children are higher
in endemic areas with moderate transmission than in endemic
areas with high transmission due to the earlier development of
clinical immunity in high transmission areas [12,13]. Other studies
have demonstrated a higher proportion of cases resulting in
cerebral malaria and a higher case fatality rate in areas with lower
transmission intensity, albeit with a lower overall malaria burden
[14] although these results are not mirrored across all studies [15].
In studies of malaria chemoprophylaxis there is good evidence of a
‘‘rebound effect’’ after chemoprophylaxis is stopped [16,17]. The
likely consequences of sustained reductions in malaria transmission
are thus very unclear [7].
Concerns about increasing incidence of disease following the
introduction of an intervention are not unique to malaria. Indeed,
over 20 years ago similar concerns arose over the introduction of a
rubella vaccine in infants. Rubella infection is of most concern if
acquired by pregnant women as it can give rise to congenital
abnormalities in the unborn child, whereas in young children
symptoms are generally mild. By reducing the overall force of
infection in the population, it was predicted that disease would
shift to older age-groups and hence the incidence of congenital
rubella syndrome may increase if vaccine coverage was not
sufficiently high [18]. More recently, Coleman et al. [19] noted
that this effect, termed ‘‘endemic stability’’ in early veterinary
research, would exist for any infectious disease in which two
conditions were met–1) disease is more likely (or more severe) in
older age-groups and 2) following an initial infection there is a
reduced probability that future infections will occur or will result in
disease.
In this paper we use a previously validated mathematical model
to explore the transient and long-term population impact of
exposure-reducing interventions for malaria [20]. This transmis-
sion model combines the development of two types of human
immunity–one which reduces the development of clinical disease
as individuals age and is dependent on past exposure and a second
age-dependent physiological process which increases the rate at
which parasites are cleared and is developed at a later age
(10 years plus). These processes were combined into a full parasite
transmission model. We use the model to explore the transient
dynamics of malaria disease incidence following different inter-
ventions, including the use of ITNs and concurrent use of either
IPT or a pre-erythrocytic stage vaccine, across a range of endemic
settings.
Methods
Model Structure and Parameters
We use a modified version of the compartmental full
transmission model described in Filipe et al. [20]. Briefly, the
model stratifies the human population into 5 states–susceptible,
exposed, clinical disease, asymptomatic infection and subpatent
infection- and the mosquito population into 3 states–susceptible,
exposed and infectious. Susceptible individuals can acquire new
infections with a force of infection dependent on the level of
infectiousness in the mosquito population. Super-infection can
lead to disease in individuals who are currently asymptomatic.
Clinical immunity develops over time dependent on the force of
infection in the population and reduces the probability that an
individual will develop clinical disease. Parasite immunity develops
as individuals’ age and reduces the amount of time spent in the
asymptomatic patent infection state (mimicking a reduction in
parasite density and hence onward infectiousness). Our previous
model fitting suggests that the loss of both clinical and parasite
immunity occurs over a period of years rather than weeks or
months [20]. Although there are relatively little data on the
duration of immunity, this is consistent with one study from
Madagascar that reported reduced rates of fever in infected
individuals born prior to the extensive successful malaria control
program initiated in the 1950’s, suggesting long-term immuno-
logical memory [21]. Full details of the model are given in
Additional Information S1.
Incorporation of interventions
We consider the impact of three interventions. Firstly, the use of
ITNs is assumed to reduce the mosquito density per person in the
community uniformly across all age-groups. Similar results are
obtained if alternatively we reduce the biting rate. Secondly we
consider the use of IPT in either infants or children aged up to
9 years of age. We assume that IPT would only be given to those
who were not showing symptoms of disease (with those individuals
showing clinical symptoms receiving treatment) and that clearance
of parasite through IPT has 70% efficacy and is rapid (mean
1 day). 70% of those who have received IPT and cleared parasites
are then fully protected from further infection for the prophylactic
period (mean of 30 or 60 days). Finally we consider the use of a
pre-erythrocytic stage vaccine which we assume provides partial
protection against infection (with the extent of protection
depending on vaccine efficacy–here we consider 30% [22,23] or
90%) through reducing the force of infection experienced in those
who are vaccinated. Individuals are vaccinated at a fixed rate set
so that 50% of the susceptible population would be vaccinated
after 5 years of a vaccination programme. We assume that those
that are infected at the time of vaccination are also successfully
treated. Following a period of time (mean of either 10 or 50 years)
the vaccine wanes but these individuals do not receive any further
vaccinations. For all three interventions we the development of
immunity is not changed i.e. individuals continue to develop
clinical immunity at rate depending on the force of infection in the
community in which they live and parasite immunity at a rate
dependent on their age.
Model Validation
In our previous model validation we focused on identification of
key parameters by matching to parasite prevalence patterns by age
across the whole age spectrum and a variety of endemic settings
[20]. In Figure 1 we show additional fits of the model to the
incidence of clinical disease by age collected from a single
comprehensive longitudinal study of malaria undertaken in two
villages (Dielmo & Ndiop) in Senegal[24] (Figure 1a) plus lifetime
clinical episodes of malaria from these two villages and Dakar
(Figure 1b) [24].
Results
Endemic settings
Our model predicts that lifetime clinical disease episodes will
peak in areas with moderate transmission (EIRs in the region 20–
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values assumed) and decrease at higher EIRs due to the exposure-
driven development of immunity. As a consequence, at any point
in time, the incidence of clinical disease is also predicted to peak in
moderate transmission settings (Figure 1d).
If exposure is reduced at a population level, for example
through the widespread use of ITNs, this will impact on
transmission, reducing the EIR. Depending on the EIR in the
setting prior to the intervention and the overall effectiveness of the
intervention in reducing transmission, there may be a negative
(Figure 2a) or positive (Figure 2b) impact on clinical disease in the
long-term. More generally, if the EIR in a setting is relatively high
then an intervention will need to be highly successful to ensure that
no increase in clinical disease occurs, whilst if the EIR is in the
range in which a peak in clinical disease incidence is predicted
(approximately 30 ibppy in this model) then even a moderately
effective intervention will reduce clinical disease incidence. These
results mirror those found more generally for the range of
infectious diseases in which endemic stability is predicted to occur
as well as in simpler models for malaria immunity [18,19,25–27].
This endemic pattern is driven in our model by the acquisition
and loss of clinical immunity which is primarily determined by the
force of infection in the population. Thus the acquisition and loss
of immunity alone can result in a pattern of ‘‘endemic stability’’ as
defined by Coleman et al. [19] without additional need to invoke
an increase in the severity of disease with age.
Transient dynamics and adverse effects of changing
incidence
The success of an intervention is typically measured by the
patterns of disease incidence in the 1–2 years following the
intervention. In Figure 2a–b we show that the population
transmission dynamics predict a transient drop in clinical disease
incidence as transmission intensity is reduced in a fully immune
population. However, we also show that, because immunity at a
population level develops (or is lost) over a period of decades, this
drop in disease level is followed by a steady rise (as immunity is
gradually lost) to a new, endemic equilibrium which is not reached
for decades (Figure 2a–b) and which can be either higher or lower
than that prior to interventions depending on transmission levels
before and after the intervention.
These epidemiological predictions should, however, be inter-
preted with caution as they assume that the effectiveness of the
intervention is sustained for many decades whereas in practice
long-term effectiveness will be affected by developing drug and
insecticide resistance, socio-demographic changes, and changes in
control and treatment policies. However, if intervention effective-
ness can not only be sustained but also improved over time, the
adverse outcome predicted in Figure 2a can be averted. For
example, Figure 2c shows a scenario in which exposure is reduced
gradually (by 5% per year rather than rapidly as in Figure 2a)
which may represent increasing coverage of ITNs or additional
interventions being implemented–for example regular indoor
Figure 1. Comparison of model output with data on the incidence of clinical disease by age and lifetime number of episodes by EIR.
The points are data and the lines denote model output. Model parameters are given in Additional Information S1 and are constant across runs except
for EIR. a–b) Incidence of clinical disease by age measured in a) Dielmo and b) Ndiop in Senegal with EIR=200 ibppy in Dielmo and 30 ibppy in Ndiop
as reported in [24]. c) Lifetime number of episodes reported from Dielmo, Ndiop and Dakar in Senegal shown as data points by EIR [24]. The line
shows the relationship between lifetime clinical episodes and EIR predicted by the model. d) Modelled relationship between EIR in endemic areas and
expected clinical episodes per person (defined as symptomatic disease which results in treatment) across all ages (in red) and in children aged 0–
9 years (in blue).
doi:10.1371/journal.pone.0004383.g001
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anophelines). Results show the impact on the incidence of clinical disease (shown in red on the left axis for figures a–d), the prevalence of
parasitaemia (shown in blue on the right axis for figures a–b) and consequent changes in the EIR (shown in green on the right axis for figures c–d).
Prior to the intervention the disease is endemic and interventions are introduced at year 0. a) Use of ITNs which lead to a continuous (but rapid)
reduction in transmission intensity from EIR=200 ibppy to EIR=30 ibppy. b) Use of ITNs which reduce the transmission intensity from EIR=30 ibppy
to EIR=5 ibppy. c) Impact of a continually improving intervention. We assume that ITNs are introduced in a setting with EIR=200 ibppy and lead to a
5% annual reduction in the EIR shown in green. d) Impact of an intervention that gradually wanes starting with EIR=200. We assume that the
reduction in mosquito density takes the form 1{21 {r ðÞ = 1zexp lt ðÞ ðÞ where r is the initial reduction, tis the time since the intervention and l=1e-3
is a parameter determining the speed of loss of effectiveness. The effect of this waning on EIR is shown in green. e) As in a) but additionally assuming
that IPTi is given at 2, 3 and 10 months of age and IPTc is given 6-monthly to children aged from 24 months to 9 years. Two scenarios for the
duration of prophylaxis are considered–30 days and 60 days. f) As in a) but with additional use of a pre-erythrocytic stage vaccine administered to the
whole population which is assumed to reduce the susceptibility to infection by either 30% (to mirror Phase II results from the RTS,S/A202A vaccine
although these results refer to morbidity rather than infection) [22,23] or 90% (an optimistic value). Two scenarios for the duration of protection are
considered–long-lived (mean 50 years) or short-lived (mean 10 years).
doi:10.1371/journal.pone.0004383.g002
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initially insufficient and results in an increase in clinical disease,
but after a longer period of time (.40 years) the EIR has declined
sufficiently to reduce clinical disease incidence below the levels
seen prior to introduction of ITNs. In this simple scenario, the
drop in clinical incidence continues until local elimination occurs
60 years after the start of the intervention. This outcome is
unlikely in practice as it relies on the assumption that the
intervention is sustained and conditions are undisturbed for
60 years. However, it also demonstrates that even local elimina-
tion would require many decades of sustained and effective control
effort.
If the effectiveness of the intervention gradually wanes, as shown
in Figure 2d, the impact on immunity is likely to be minimal and
the incidence of clinical disease will return to pre-intervention
settings. However, unexpected temporal patterns in disease
incidence may occur. For example, if the intervention is
introduced in a high transmission setting and is initially very
successful we may observe an initial transient drop in clinical
disease incidence, followed some 10 years later by a rise towards a
peak in incidence higher than prior to the intervention, before
clinical incidence returns to pre-intervention levels (Figure 2d).
This ‘zig-zag’ behaviour results from the trade-off between a
steady rebound in EIR and a loss followed by a regain of
protective immunity at a population level. A naive interpretation
of such a transient pattern would be that the intervention is
initially very successful (drop in incidence), then begins to fail (as
incidence increases) and in a third phase improves as incidence
decreases. During the second and third stages of this process, the
naı ¨ve interpretation may be incorrect (or at least incomplete) and
may lead to erroneous decision making.
Combining interventions to reduce the chance of
adverse outcomes
An alternative option to prevent any adverse outcome of an
exposure-reducing intervention would be to incorporate multiple
interventions simultaneously. Figure 2e shows the potential impact
of the same exposure-reducing intervention as Figure 2a, but this
time supplemented with extensive IPTi and IPTc. IPT in infants
(age,1 year) provides little additional protection since as the EIR
is reduced through ITNs the burden of disease is predicted to shift
to young children (aged 2–5 years). However, a comprehensive
IPT intervention in children (6-monthly treatment of children
aged 2–9 years with an efficacious long-acting drug such as
mefloquine or piperaquine over a 30-day prophylactic period) can
significantly reverse the adverse outcome of other interventions.
Furthermore, if a drug with a longer prophylactic period (in the
example here 60 days) or more-frequent treatment is used then the
adverse outcome initially predicted could be completely prevented.
Vaccination could also be combined with exposure-reducing
interventions. Figure 2f shows the impact of a pre-erythrocytic
vaccine which, for simplicity, we assume reduces the risk of
infection but does not affect the development of clinical immunity.
Under the characteristics of the current vaccination under
consideration (RTS,S/A202A–which provides ,30% efficacy
against malarial morbidity [22,23]) the adverse outcome can be
reduced but not completely reversed, even if the duration of
protection provided by the vaccine is very long. However, a
vaccine with substantially higher efficacy (e.g. one with 90%
efficacy) could be beneficial and prevent the adverse outcome if
the duration of protection is sufficiently long (or if the duration is
extended with a boosting programme). Thus it is clear that by
combining interventions that act in different ways the adverse
outcomes predicted by our model could be substantially or almost
completely negated.
Monitoring for increases in the incidence of clinical
disease
Given the many uncertainties in malaria transmission dynamics
and limitations in its monitoring, it will be difficult to assess which
if any of the scenarios outlined above may occur once interven-
tions are introduced. Thus it is of interest to identify a group of
individuals in whom any adverse results would be detected early.
Figure 3 shows that a larger relative increase in incidence of
clinical disease compared to pre-intervention levels will be
observed in children aged 5–9 years (who will fail to acquire any
protective immunity) and hence this may be the best group to
monitor for rebound effects in the early years of a control
programme. Infants and younger children will continue to benefit
from protection conferred by maternal immunity (which depends
on transplacental transfer of antimalarial antibodies and is likely to
persist in the mother for some years in the absence of ongoing
infection [28]) and so will experience a greater drop in clinical
incidence until their mothers’ immunity has waned, after which
more rapid rises in clinical disease are predicted.
Discussion
Our results demonstrate that the higher incidence of clinical
malaria that has been observed in moderate transmission settings
relative to high transmission settings [24] may be a result of
‘‘endemic stability’’ driven by the rapid development of clinical
immunity in high transmission settings. This mechanism alone
appears to reproduce the patterns of clinical disease by
transmission setting without additionally incorporating a mecha-
nism by which the severity of disease increases with age (as
postulated in Coleman et al. [19]). We believe that our model for
the acquisition and loss of immunity adequately mimics the
biology of the infection and its potential impact on all clinical
disease. However, this does not exclude other factors being
involved in producing this pattern, such as purely physiological
effects which are likely to determine the spectrum of disease at
different ages.
Figure 3. Impact of a sustained ITN intervention on disease
incidence in infants and young children. A reduction in EIR from
200 to 30 ibppy is assumed (as in Figure 2a).
doi:10.1371/journal.pone.0004383.g003
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dynamics of malarial disease incidence following an intervention.
Whilst, given the absence of detailed longitudinal data, it is
impossible to precisely define the timescale of the transient impact
of any intervention, our results suggest that these timescales will be
in the order of many years to decades. Furthermore, our examples
illustrate that in the years following an intervention we may initially
see a temporary decline in incidence (as a result of a decline in
transmission intensity in a highly immune population) whereas
after this time disease incidence could, in the worst scenarios,
increase to higher levels than prior to the intervention. It is
important to emphasise that this eventual increase in disease
incidence does not necessarily indicate any loss of effectiveness of
the intervention. Such adverse scenarios are characteristics of
settings in which endemic stability dominates, and indeed similar
transient dynamics were predicted for the impact of rubella
vaccination on congenital rubella syndrome in developing
countries and for chemotherapy and vaccination against helminth
infections [18,26]. Furthermore, the initial rapid declines in
incidence predicted by our model appear consistent with those
observed in studies of the introduction of ITNs reported to date [2].
However, our results also demonstrate that such adverse scenarios
can be avoided by combining transmission-reducing interventions
with either a partially-effective vaccine or prophylactic therapy,
and ensuring that the effectiveness of the interventions is sustained
over many years. To ensure that this goal is achieved, both the
intervention itself and monitoring for any negative effects must
remain in place for many years, possibly decades.
One important aspect not addressed here is the relationship
between overall clinical disease and severe disease and childhood
mortality. Because of the complex disease spectrum and the
relationship between severe disease and age, the basis of which is
not yet fully understood, we chose not to explicitly incorporate this
directly in our model. However, there is substantial evidence
demonstrating that severe malarial anaemia peaks in infants under
2 years of age in high transmission settings whereas cerebral
malaria is more common in children over 5 years of age in lower
transmission settings [14]. Hence any shift in disease incidence
into older age-groups is also likely to give rise to shift in clinical
presentation of severe malaria disease.
Clearly there are limitations to any modelling exercise.
Although we were able to validate the static aspects of our model
over the whole age range of populations across a wide variety of
endemic settings, there are limited data from longitudinal studies
with which to validate the dynamics. Secondly, whilst one may
argue that some aspects of malaria epidemiology are not well-
captured within our proposed compartmental framework, we
believe that it captures the main features of malaria epidemiology
that will impact at a qualitative level on the dynamics of disease
incidence following an intervention. Finally, in our scenarios we
assume that each individual is protected by both the exposure-
reducing interventions and the prophylactic therapy or vaccina-
tion that they receive, but continue through this period to develop
clinical immunity at a rate dependent on the overall level of
transmission in the community in which they live. There is some
evidence that the development of acquired immunity to malaria is
enhanced in partially-protected individuals, particularly under
high transmission [9,29]. Such a scenario would reduce the chance
of adverse outcomes as transmission is reduced from high to
moderate levels.
How then should we assess the impact of future exposure-
reducing interventions? Firstly, a clearer understanding of the
development of acquired immunity is critical to these hypotheses
and hence interpretation of all intervention studies. The
predictions of our two-stage immunity model depend on the
degree of exposure that is required to develop immunity and the
timescales over which immunity is gained and lost. In this work we
assume that clinical immunity is developed at a rate proportional
to the EIR in each setting and has a half-life of approximately
7 years, and that parasite-clearance immunity has a half-life of
approximately 14 years. The former parameter is particularly
important in the predictions made here (see Additional Informa-
tion S1). These parameters reproduce epidemiological patterns
[20] and are consistent with epidemiological observation [21] but
have not been formally measured in any malaria endemic setting.
Improving our understanding of immunity mechanisms requires
long-term monitoring of immunological markers and clinical
disease episodes in cohorts of individuals in different malaria
endemic settings. Secondly, the model highlights the need for
detailed assessment of the current endemic levels of disease prior to
interventions being scaled up. Recent research undertaken as part
of the Malaria Atlas Project has gone some way to achieve this and
suggests that high EIR settings may be less common than
previously believed [30]. If this is the case then the adverse
scenarios that we describe may occur infrequently. Thirdly, whilst
studies have demonstrated a significant reduction in mortality or
clinical disease in the months or years after a successful
intervention, longer-term follow-up of protected communities is
important in order to monitor subsequent impact and to
differentiate it from reductions in transmission through e.g.
changing climate and social improvements. Finally, the shape of
the long-term relationship between exposure (EIR) and clinical
disease in our model demonstrates that, if multiple effective
interventions are implemented, concurrently, with high coverage,
it is possible to offset the negative impact of reducing immunity
through driving transmission to low levels [14]. In fact, as EIR falls
and there are fewer immune individuals, the proportion of
asymptomatic infections will also fall and thus a greater proportion
of infected people will seek antimalarial treatment. Under these
conditions, prompt treatment of cases with a highly effective
antimalarial regimen can contribute significantly to transmission
reduction [31,32]. Several countries in sub-Saharan Africa have
free distribution of long-lasting ITNs supplemented by rounds of
insecticide-residual spraying and have changed first-line therapy to
artemisinin-based combinations. Sustaining both control interven-
tions and effective case management for many years, possibly
decades, should remain the primary goal of all intervention
programmes and it is essential that these long-term goals are
matched with financial commitments.
Supporting Information
Additional Information S1 Mathematical details of the model
and parameter sensitivity analysis
Found at: doi:10.1371/journal.pone.0004383.s001 (0.24 MB
DOC)
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